National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease

By Bradley T. Hyman, C. Phelps, Thomas G. Beach, Eileen Bigio, N. Cairns, Maria C. Carrillo, Dennis W. Dickson, C. Duyckaerts, M. Frosch, E. Masliah and 8 more. Alzheimer's & Dementia, 2012

2,830 citations recorded by the source corpus.

A consensus panel from the United States and Europe was convened recently to update and revise the 1997 consensus guidelines for the neuropathologic evaluation of Alzheimer's disease (AD) and other diseases of brain that are common in the elderly. The new guidelines recognize the pre‐clinical stage of AD, enhance the assessment of AD to include amyloid accumulation as well as neurofibrillary change and neuritic plaques, establish protocols for the neuropathologic assessment of Lewy body disease, vascular brain injury, hippocampal sclerosis, and TDP‐43 inclusions, and recommend standard approaches for the workup of cases and their clinico‐pathologic correlation.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/15a755fb7f8613d7e2c0d3f4bd7c28a9af9800b0

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

2016 Alzheimer's disease facts and figures (2016, positive): “In 2012, the NIA and the Alzheimer’s Association also developed new guidelines to help pathologists describe and categorize the brain changes associated with Alzheimer’s disease and other dementias on autopsy [111].”
Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models (2014, background): “In 2012, new consensus guidelines for neuropathologic evaluation of AD were adopted (Hyman et al., 2012; Montine et al., 2012).”
The evolution of preclinical Alzheimer’s disease: Implications for prevention trials (2014, positive): “propagation that extends the distribution of Tau pathology to limbic and neighboring temporal neocortex (Braak III–IV and higher) and is thought to mark the transition from asymptomatic to symptomatic pathology (Hyman et al., 2012; Nelson et al., 2012; Price and Morris, 1999).”
Alzheimer's disease (2018, background): “Updated National Institute on Aging and the Alzheimer’s Association (NIA-AA) neuropathological guidelines attempt to address this, acknowledging the potential for disconnect between the clinical picture and neuropathological changes [22].”
Primary age-related tauopathy (PART): a common pathology associated with human aging (2014, background): “A diagnosis of AD neuro-pathologic changes requires at least a minimum threshold level of A β deposition [64, 102].”
Proteopathic tau seeding predicts tauopathy in vivo (2014, methodology): “Histopathological analysis has been widely used to quantify tau deposition and is currently the gold standard for postmortem diagnosis of AD and the related tauopathies (41, 42).”
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, positive): “It is worthwhile emphasizing that, like the 2012 NIA-AA classification system for AD neuropathic change [105,106], AT(N) scoring of biomarkers is independent from clinical symptoms.”